CN100579525C - Sustained release preparation of licardipine hydrochloride and its preparing process - Google Patents
Sustained release preparation of licardipine hydrochloride and its preparing process Download PDFInfo
- Publication number
- CN100579525C CN100579525C CN200710019925A CN200710019925A CN100579525C CN 100579525 C CN100579525 C CN 100579525C CN 200710019925 A CN200710019925 A CN 200710019925A CN 200710019925 A CN200710019925 A CN 200710019925A CN 100579525 C CN100579525 C CN 100579525C
- Authority
- CN
- China
- Prior art keywords
- release
- hydrochloride
- preparation
- micropill
- licardipine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
The invention relates to a method for preparing Licardipine Hydrochloride slow-release agent, which can be used to treat hypertension, coronary disease or the like. The inventive slow-release agent is formed by quick-release stomach-soluble micro drop and slow-release enteric-soluble micro drop at 1:0.5-5 ratios in the hollow capsule. The inventive capsule has slow-release effect in 12 hours. The slow-release enteric-soluble micro drop comprises Licardipine Hydrochloride, medical macromolecule materials, drug release adjusting agent and some medical finding. The micro drops are prepared by extruding-rolling technique. The invention can quickly approach the blood drug density to treatment object and hold the density stably, with low side effect.
Description
Technical field
Specifically a kind of anginal sustained release preparation of licardipine hydrochloride of essential hypertension, coronary heart disease and all kinds that cures mainly of the present invention relates to technical field of medicine.
Background technology
Hypertension is the important risk factor of cardiovascular and cerebrovascular disease.In the crowd of any age, sex, the dangerous of cardiovascular and cerebrovascular disease all is proportionate with hypertension, thereby should strengthen control to hypertension, thereby reduces the incidence rate and the mortality rate of the heart, cerebrovascular disease.Senile hypertension patient's target organ damages more, how with phenomenons such as coronary heart disease, angina pectoris, renal insufficiencys.Therefore, many countries have carried out the research of disease medicaments such as clinical resisting hypertension, angina pectoris, coronary heart disease.At present, the existing types of drugs that is used for treating cardiovascular and cerebrovascular diseases such as hypertension has a lot, as sympathetic inhibitor, beta-blocker and calcium ion antagonist etc. behind diuretic, adrenergic nerve inhibitor, vasodilation, angiotensin-convertion enzyme inhibitor, 5-hydroxytryptamine receptor antagonist, neuroganglion and the joint, majority can only reach 50%～60% antihypertensive effect, and prolonged application also may produce some untoward reaction.
Licardipine Hydrochloride (Nicardipine Hydrochloride) is a dihydropyridine class calcium antagonist, its chemical name is: 2, and 6-dimethyl 4-(3-nitrobenzophenone)-1,4-dihydropyridine-3, the 5-dihydroxy acid, 3-[β-(N-benzyl-N-methylamino)] ethyl ester-5-methyl ester hydrochloride; Molecular formula is: C
26H
29N
3O
6HCl; Molecular weight is: 515.99.Licardipine Hydrochloride has advantages such as action range, evident in efficacy, little to cardiac function influence, few side effects.Be widely used in treating diseases such as essential hypertension, coronary heart disease, angina pectoris clinically, its main mechanism is to suppress cardiac muscle not change blood calcium concentration with the striding the film flow of calcium ions of vascular smooth muscle; Blood vessel is had the selectivity of height, the calcium antagonism of vascular smooth muscle is better than effect to cardiac muscle; No arrhythmia effect does not also have arrhythmogenic effect; Can improve the compliance of tremulous pulse, postpone atherosclerotic generation; The existing myocardial oxygen of Licardipine Hydrochloride has the effect that reduces myocardium keto consumption again, so can increase the motion dosis tolerata of patients with stable angina, reduces the angina pectoris attacks frequency.The hypotensive effect of Licardipine Hydrochloride is the expansion small artery, reduces total peripheral vascular resistance, and does not influence sympathetic activity.
Licardipine Hydrochloride is in being used for the treatment of cardiovascular and cerebrovascular disease processes such as essential hypertension, its effective percentage to each phase hyperpietic is: the I phase 92.7%, the II phase 90.8%, the III phase 81.1%, the prolonged application antihypertensive effect can reach more than 80%, and the cardiopulmonary kidney is had no adverse effects, and is current comparatively ideal antihypertensive drugs, the choice drug of Chang Zuowei blood pressure lowering clinically.But the biological half-life of this medicine is short, in order to keep curative effect preferably, stablizes patient's blood pressure, need take medicine on time, and causes patient's frequently take medicine (administration every day 3～4 times).Because the heart, cerebrovascular disease are burst easily, and " drug withdrawal knock-on " occur in some patient that can not take medicine on time, tend to serious harm patient's life security.And conventional formulation, blood concentration fluctuation is big, and some adverse side effects easily take place, and is unfavorable for patient's medication.
The conventional tablet of the existing rapid release of list marketing Licardipine Hydrochloride oral formulations has the slow releasing preparation of keeping the long period curative effect again at present.Because conventional tablet will be taken medicine 3～4 times in use every day, and the back blood concentration fluctuation of taking medicine is bigger, and therefore the compliance of taking medicine is relatively poor, and untoward reaction is also obviously on the high side.Sustained release preparation of licardipine hydrochloride uses comparatively extensive clinically.Develop the Japanese Yamanouchi Pharmaceutical Co., Ltd of sustained release preparation of licardipine hydrochloride the earliest, the commodity that go on the market in China are: the perdipine slow releasing capsule.This product is by medicated powder on celphere, and the method for wrapping pH dependent form release-controlled film again makes slow-release micro-pill.Chinese patent 03110949.7 disclose a kind of in gastrointestinal tract environment the slow releasing preparation of the Licardipine Hydrochloride of controlled release, use laser drilling on the tablet coating film, to play a drug release hole, can reach the effect of continuous release in 24 hours.
The medicated powder legal system is equipped with the Nicardipine hydrochloride sustained-release micropill and can obtains the bead that outward appearance is regular, be easy to coating on the celphere, but production process needs powder coating equipment on the expensive fluid bed, in order to determine to go up dose, also must carry out the pilot process control of strict control, and the yield rate of producing is not high.The present invention has overcome above-mentioned shortcoming.
Summary of the invention
Technical problem: the purpose of this invention is to provide a kind of sustained release preparation of licardipine hydrochloride and preparation method thereof, slow releasing preparation is control drug release speed effectively, reduces untoward reaction, reduces administration number of times, and drug compliance is good.The production technology of this sustained release preparation of licardipine hydrochloride should be relatively simple, and production process is easy to control, yield rate height.
Technical scheme: sustained release preparation of licardipine hydrochloride of the present invention is made up of the gastric solubleness micropill and the slow release enteric coated micropill of rapid release; Gastric solubleness micropill and enteric coated micropill mix the Capsules of packing into by 1: 0.5～5, make the slow releasing capsule of hydrochloric nicardipine, and this capsule had slow release effect in 12 hours.
Consisting of of the gastric solubleness micropill of Licardipine Hydrochloride rapid release: Licardipine Hydrochloride accounts for 5～30%; Filler accounts for 60～90%; Disintegrating agent accounts for 3～10%; Other adjuvant accounts for 5～32%.
Described filler is: the mixture of any one in the solubility filleies such as lactose, mannitol, sucrose, glucose, sorbitol or multiple and microcrystalline Cellulose; Described disintegrating agent is: any one in crospolyvinylpyrrolidone, carboxymethyl starch sodium, low-substituted hydroxypropyl cellulose, the cross-linking sodium carboxymethyl cellulose etc. or multiple combination.
Consisting of of Nicardipine hydrochloride sustained-release enteric coated micropill: Licardipine Hydrochloride accounts for 5～30%; Pharmaceutical polymers accounts for 5～20%; Medicine stripping regulator accounts for 0.1～5.0%; Other adjuvant accounts for 45～90%.
Pharmaceutical polymers be can dissolve under the intestinal PH environment and in gastric juice insoluble macromolecular material.
Described macromolecular material is methacrylic acid-methylmethacrylate copolymer, cellulose derivative.
Methacrylic acid-methylmethacrylate copolymer is meant EUDRAGIT L100-55, EUDRAGITL100, EUDRAGIT S100 and EUDRAGIT L30D0-55.
Cellulose derivative is meant Hydroxypropyl Methylcellulose Phathalate (HPMCP), cellulose acetate-phthalate (CAP) and hydroxypropyl emthylcellulose acetic acid succinate (HPMCAS).
Medicine stripping regulator is meant that aqueous solution shows tart salts substances, specifically is meant ammonium chloride, potassium dihydrogen phosphate, sodium dihydrogen phosphate, diethylamine hydrochloride and triethylamine hydrochloride.
Said preparation by gastric solubleness micropill and enteric coated micropill by 1: 0.5～5 mixed after fill in capsule, make, wherein: the preparation method of Nicardipine hydrochloride sustained-release enteric coated micropill is: except that medicine stripping regulator, each raw material is done mixed, the aqueous solution that is dissolved with medicine stripping regulator is made soft material as wetting agent, via hole diameter is extruded for the 0.5-1.5mm web plate, rotating speed is the round as a ball 5-20min of 250-600r/min, 40 ℃ of dryings; The preparation method of the gastric solubleness micropill of described Licardipine Hydrochloride rapid release is: after each material do is mixed, use water as wetting agent and make soft material, via hole diameter is extruded for the 0.5-1.5mm web plate, and rotating speed is that 250-600r/min is round as a ball, 40 ℃ of dryings.
Beneficial effect: by the analytical test result as can be known: this Nicardipine hydrochloride sustained-release capsule has the good slow release effect, and can discharge the Licardipine Hydrochloride of effective dose in hydrochloric acid solution in the short period of time, guarantees rapid-action.In enteric liquid, this Nicardipine hydrochloride sustained-release capsule can be guaranteed steadily to discharge Licardipine Hydrochloride in 12 hours, plays steady blood pressure lowering effect.
The specific embodiment
Employing extrudes-and spheronization technique prepares Licardipine Hydrochloride gastric solubleness micropill and enteric coated micropill.The gastric solubleness micropill is at acid solution energy rapid release Licardipine Hydrochloride, and enteric coated micropill has slow releasing function in enteric liquid.Licardipine Hydrochloride gastric solubleness micropill and enteric coated micropill by 1: 0.5～5 mixed, should be mixed micropill again and poured into capsule.
The prescription of enteric-coated sustained release micropill is as follows, by mass percentage.
Principal agent: Licardipine Hydrochloride 5～30%
Adjuvant:
Pharmaceutical polymers 5～20%
Medicine stripping regulator 0.1～5.0%
Other adjuvant surplus
Pharmaceutical polymers in the above-mentioned prescription be meant can dissolve under the intestinal PH environment and in gastric juice insoluble macromolecular material, as methacrylic acid-methylmethacrylate copolymer, cellulose derivative.Here methacrylic acid-the methylmethacrylate copolymer that refers to can be EUDRAGIT L100-55, EUDRAGIT L100, EUDRAGIT S100 and EUDRAGIT L30D0-55; Here the cellulose derivative that refers to can be Hydroxypropyl Methylcellulose Phathalate (HPMCP), cellulose acetate-phthalate (CAP) and hydroxypropyl emthylcellulose acetic acid succinate (HPMCAS).
Medicine stripping regulator in the above-mentioned prescription is meant that the adjustment by pH value influences the medicine dissolution rate, shows tart salts substances as aqueous solution: ammonium chloride, potassium dihydrogen phosphate, sodium dihydrogen phosphate, diethylamine hydrochloride, triethylamine hydrochloride.
Other adjuvant in the above-mentioned prescription is meant filler commonly used in the pharmaceutical preparation: any one in lactose, mannitol, sucrose, glucose, sorbitol, starch, modified starch and the microcrystalline Cellulose etc. or multiple combination.
Other adjuvant in the above-mentioned prescription also refers to binding agent commonly used in the pharmaceutical preparation: any one in polyvinylpyrrolidone, the hydroxypropyl emthylcellulose etc. or multiple combination.
Other adjuvant in the above-mentioned prescription also refers to disintegrating agent commonly used in the pharmaceutical preparation: any one in crospolyvinylpyrrolidone, carboxymethyl starch sodium, low-substituted hydroxypropyl cellulose, the cross-linking sodium carboxymethyl cellulose etc. or multiple combination.
Other adjuvant in the above-mentioned prescription also refers to any one or the multiple combination in lubricant: PEG4000, PEG4000, magnesium stearate, the Pulvis Talci, micropowder silica gel etc.
Except that medicine stripping regulator, above-mentioned each raw material is fully mixed by the prescription proportioning.The aqueous solution that is dissolved with medicine stripping regulator is made soft material as wetting agent, adopt to extrude-spheronization technique prepares the Licardipine Hydrochloride enteric sustained-release pellet.The aperture of extruding with web plate is 0.5-1.5mm.Round as a ball rotating speed is 250-600r/min.Round as a ball time 5-20min.It is 0.8-1.2mm that the best is extruded with the web plate aperture.Best round as a ball rotating speed is 400-500r/min.Round as a ball time 10-12min.Through the round as a ball Licardipine Hydrochloride enteric coated micropill that makes at 40 ℃ of hot air dryings, dry to water content below 3%.
Measure the drug release situation of this Licardipine Hydrochloride enteric coated micropill by two appendix XD first methods of Chinese Pharmacopoeia version in 2005.Release medium is that phosphate buffer (is got potassium dihydrogen phosphate 6.8g and 1g polyoxyethylene sorbitan monoleate, add water 900ml and make dissolving,, add water to 1000ml with sodium hydroxide test solution adjust pH to 6.5 soil 0.05) 900ml, rotating speed was 150r/min, at 1,2,4,6,10 hour sample analysis.The result shows that this enteric coated micropill has the good slow release effect, and total burst size of 10 hours is greater than 80%.
Medicine stripping regulator has fairly obvious influence to the drug release situation, the micropill of selecting for use the lower salt of pH to make, and drug release is accelerated.The model of pharmaceutical polymers and consumption also have bigger influence to drug release.Can obtain needed slow-release micro-pill by kind and the consumption of selecting pharmaceutical polymers and medicine stripping regulator.Also there are bigger influence rotating speed and round as a ball time when in addition, round as a ball to drug release.
The prescription of gastric solubleness micropill is as follows, by mass percentage.
Principal agent: Licardipine Hydrochloride 5～30%
Adjuvant:
Filler 60～90%
Disintegrating agent 3～10%
Other adjuvant surplus
Filler in the above-mentioned prescription: any one in the solubility filleies such as lactose, mannitol, sucrose, glucose, sorbitol or multiple combination and microcrystalline Cellulose.
Disintegrating agent in the above-mentioned prescription: any one in crospolyvinylpyrrolidone, carboxymethyl starch sodium, low-substituted hydroxypropyl cellulose, the cross-linking sodium carboxymethyl cellulose etc. or multiple combination.
Other adjuvant in the above-mentioned prescription is meant: adjuvants such as the binding agent of using always in the solid orally ingestible, lubricant.
The preparation process of gastric solubleness micropill adopts and extrudes-spheronization technique with above-mentioned enteric coated micropill preparation process, makes wetting agent with water.Technological parameter also prepares with enteric coated micropill.
Measure the drug release of this Licardipine Hydrochloride gastric solubleness micropill by two appendix XD first methods of Chinese Pharmacopoeia version in 2005.Release medium was the hydrochloric acid 900ml of 0.1mol/L, and rotating speed is 150r/min, at 0.25,0.5,1,2 hour sample analysis.The result shows that this gastric solubleness micropill promptly had 80% drug release at 0.25 hour, and drug release reached more than 95% in 1 hour.
Said preparation by gastric solubleness micropill and enteric coated micropill by 1: 0.5～5 mixed after fill in capsule, make, wherein: the preparation method of Nicardipine hydrochloride sustained-release enteric coated micropill is: except that medicine stripping regulator, each raw material is done mixed, the aqueous solution that is dissolved with medicine stripping regulator is made soft material as wetting agent, via hole diameter is extruded for the 0.5-1.5mm web plate, rotating speed is the round as a ball 5-20min of 250-600r/min, 40 ℃ of dryings; The preparation method of the gastric solubleness micropill of described Licardipine Hydrochloride rapid release is: after each material do is mixed, use water as wetting agent and make soft material, via hole diameter is extruded for the 0.5-1.5mm web plate, and rotating speed is that 250-600r/min is round as a ball, 40 ℃ of dryings.
Embodiment 1: the preparation of Licardipine Hydrochloride gastric solubleness micropill
Prescription
| Principal agent and adjuvant title | Weight (gram) |
| Licardipine Hydrochloride | 20 |
| Microcrystalline Cellulose | 20 |
| Lactose | 130 |
| Carboxymethyl starch sodium | 18 |
| Polyvinylpyrrolidone K-30 | 12 |
| Purified water | 80 |
Preparation process
12g polyvinylpyrrolidone K-30 is dissolved in the 80ml purified water makes wetting agent.Licardipine Hydrochloride 20g, lactose 130g, microcrystalline Cellulose 20g, carboxymethyl starch sodium 12g are fully mixed, cross 60 mesh sieves.Wetting agent is added in the dry powder that mixes, and high-speed stirred 5 minutes gets soft material.Soft material is extruded through the 1.0mm hole pattern, handled 10 minutes on spheronizator, rotating speed is 500 rev/mins.The wet micropill that obtains was 40 ℃ of following forced air dryings 4 hours, and sieve is got 24-40 purpose micropill, yield rate 92%.
Embodiment 2: the preparation of Licardipine Hydrochloride gastric solubleness micropill
Prescription
| Principal agent and adjuvant title | Weight (gram) |
| Licardipine Hydrochloride | 20 |
| Microcrystalline Cellulose | 33 |
| Mannitol | 130 |
| Low-substituted hydroxypropyl cellulose | 15 |
| Polyvinylpyrrolidone K-30 | 12 |
| Purified water | 80 |
Preparation process
Preparation process is identical with embodiment 1, only be with lactose replace to mannitol, carboxymethyl starch sodium changes low-substituted hydroxypropyl cellulose into.Yield rate 88%.
Embodiment 3: the preparation of Nicardipine hydrochloride sustained-release enteric coated micropill
Prescription
| Principal agent and adjuvant title | Weight (gram) |
| Licardipine Hydrochloride | 40 |
| EUDRAGIT L100-55 | 25 |
| Potassium dihydrogen phosphate | 5 |
| Microcrystalline Cellulose | 26 |
| Lactose | 89 |
| Carboxymethyl starch sodium | 5 |
| Polyvinylpyrrolidone K-30 | 6 |
| PEG4000 | 4 |
| Purified water | 80 |
Preparation process
With Licardipine Hydrochloride 40g; Lactose 89g; Microcrystalline Cellulose, 26g; EUDRAGIT L100-55,25g; Carboxymethyl starch sodium 5g; PEG4000,4g fully mixes, and crosses 60 mesh sieves.After 5g potassium dihydrogen phosphate and 6g polyvinylpyrrolidone K-30 be dissolved in the 80ml purified water, be added in the dry powder that mixes, high-speed stirred 5 minutes makes soft material.Extrude through the 1.0mm hole pattern, handled 10 minutes on spheronizator, rotating speed is 400 rev/mins.The wet micropill that obtains was 40 ℃ of following forced air dryings 4 hours.Sieve is got 24 orders--40 purpose micropills.Nicardipine hydrochloride sustained-release enteric coated micropill yield 85%.
The preparation of embodiment 4 Nicardipine hydrochloride sustained-release enteric coated micropills
Prescription
| Principal agent and adjuvant title | Weight (gram) |
| Licardipine Hydrochloride | 40 |
| EUDRAGIT S100 | 22 |
| Ammonium chloride | 8 |
| Microcrystalline Cellulose | 25 |
| Lactose | 90 |
| Carboxymethyl starch sodium | 5 |
| Polyvinylpyrrolidone K-30 | 6 |
| PEG4000 | 4 |
| Purified water | 80 |
Preparation process
Preparation process is identical with embodiment 3, only be with EUDRAGIT L100-55 replace to EUDRAGITS100, potassium dihydrogen phosphate replaces to ammonium chloride.Nicardipine hydrochloride sustained-release enteric coated micropill yield rate 83%.
The preparation of embodiment 5 Nicardipine hydrochloride sustained-release enteric coated micropills
Prescription
| Principal agent and adjuvant title | Weight (gram) |
| Licardipine Hydrochloride | 40 |
| Hydroxypropyl Methylcellulose Phathalate (HPMCP) | 20 |
| Diethylamine hydrochloride | 6 |
| Microcrystalline Cellulose | 25 |
| Lactose | 60 |
| Mannitol | 34 |
| Crospolyvinylpyrrolidone | 5 |
| Polyvinylpyrrolidone K-30 | 10 |
| Purified water | 80 |
Preparation process
With Licardipine Hydrochloride 40g; Lactose 60g; Lactose 34g; Microcrystalline Cellulose, 25g; Hydroxypropyl Methylcellulose Phathalate (HPMCP) 20g; Crospolyvinylpyrrolidone 5g fully mixes, and crosses 60 mesh sieves.After 6g diethylamine hydrochloride and 10g polyvinylpyrrolidone K-30 be dissolved in the 80ml purified water, be added in the dry powder that mixes, high-speed stirred 5 minutes makes soft material.Extrude through the 0.8mm hole pattern, handled 10 minutes on spheronizator, rotating speed is 450 rev/mins.The wet micropill that obtains was 40 ℃ of following forced air dryings 4 hours.Sieve is got 24 orders--40 purpose micropills.Nicardipine hydrochloride sustained-release enteric coated micropill yield 82%.
The preparation of embodiment 6 Nicardipine hydrochloride sustained-release enteric coated capsulees
Prescription
Preparation process
Licardipine Hydrochloride gastric solubleness micropill 110g, sour nicardipine enteric coated micropill 150g and micropowder silica gel 2g are fully mixed.Divide to be filled in No. 2 Capsuleses the micropill about 255mg of packing in every capsules.The capsular specification of the Nicardipine hydrochloride sustained-release that makes like this is: 40 milligrams/(in Licardipine Hydrochloride).
Analyze contrast
According to drug standard WS1-(the X-316)-2003Z of State Food and Drug Administration issue, the Nicardipine hydrochloride sustained-release capsule of gained is carried out the release analysis
| Dissolution time | 1 hour | 2 hours | 4 hours | 8 hours | 12 hours |
| Dissolution medium | 900ml hydrochloric acid solution (get hydrochloric acid 14ml, add sodium chloride 4g, add water and make dissolving, and be diluted to 2000ml) | The 900ml phosphate buffer (contains 0.1% polyoxyethylene sorbitan monoleate, pH=6.5) | Dissolution medium was with 2 hours | Dissolution medium was with 2 hours | Dissolution medium was with 2 hours |
| The hydrochloric acid Buddhist nun blocks the ground burst size | 27％ | 32％ | 49％ | 73％ | 87％ |
Annotate: in hydrochloric acid solution, be released into 1 hour, promptly leach insoluble matter, put into phosphate buffer and carry out release test.
By the analytical test result as can be known: this Nicardipine hydrochloride sustained-release capsule has the good slow release effect, and can discharge the Licardipine Hydrochloride of effective dose in hydrochloric acid solution in the short period of time, guarantees rapid-action.In enteric liquid, this Nicardipine hydrochloride sustained-release capsule can be guaranteed steadily to discharge Licardipine Hydrochloride in 12 hours, plays steady blood pressure lowering effect.
Claims (4)
1. sustained release preparation of licardipine hydrochloride is characterized in that this slow releasing preparation is made up of the gastric solubleness micropill and the slow release enteric coated micropill of rapid release; Gastric solubleness micropill and enteric coated micropill mix the Capsules of packing into by 1: 0.5～5, make the slow releasing capsule of hydrochloric nicardipine, and this capsule had slow release effect in 12 hours;
The percentage by weight of the gastric solubleness micropill of Licardipine Hydrochloride rapid release consists of: Licardipine Hydrochloride accounts for 5～30%; Filler accounts for 60～90%; Disintegrating agent accounts for 3～10%; Surplus is other adjuvant;
The percentage by weight of Nicardipine hydrochloride sustained-release enteric coated micropill consists of: Licardipine Hydrochloride accounts for 5～30%; Pharmaceutical polymers accounts for 5～20%; Medicine stripping regulator accounts for 0.1～5.0%; Surplus is other adjuvant;
Described macromolecular material is methacrylic acid-methylmethacrylate copolymer;
Medicine stripping regulator is meant that aqueous solution shows tart salts substances, specifically is meant ammonium chloride, potassium dihydrogen phosphate, sodium dihydrogen phosphate, diethylamine hydrochloride or triethylamine hydrochloride.
2. sustained release preparation of licardipine hydrochloride according to claim 1 is characterized in that described filler is: the mixture of any one in lactose, mannitol, sucrose, glucose, the sorbitol or multiple and microcrystalline Cellulose; Described disintegrating agent is: any one in crospolyvinylpyrrolidone, carboxymethyl starch sodium, low-substituted hydroxypropyl cellulose, the cross-linking sodium carboxymethyl cellulose or multiple combination.
3. sustained release preparation of licardipine hydrochloride according to claim 1 is characterized in that methacrylic acid-methylmethacrylate copolymer is meant EUDRAGIT L100-55, EUDRAGIT L100, EUDRAGITS100 or EUDRAGIT L30D0-55.
4. the preparation method of a sustained release preparation of licardipine hydrochloride as claimed in claim 1, it is characterized in that said preparation by gastric solubleness micropill and enteric coated micropill by 1: 0.5～5 mixed after fill in capsule, make, wherein: the preparation method of Nicardipine hydrochloride sustained-release enteric coated micropill is: except that medicine stripping regulator, each raw material is done mixed, the aqueous solution that is dissolved with medicine stripping regulator is made soft material as wetting agent, via hole diameter is extruded for the 0.5-1.5mm web plate, rotating speed is the round as a ball 5-20min of 250-600r/min, 40 ℃ of dryings; The preparation method of the gastric solubleness micropill of described Licardipine Hydrochloride rapid release is: after each material do is mixed, use water as wetting agent and make soft material, via hole diameter is extruded for the 0.5-1.5mm web plate, and rotating speed is that 250-600r/min is round as a ball, 40 ℃ of dryings.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200710019925A CN100579525C (en) | 2007-02-02 | 2007-02-02 | Sustained release preparation of licardipine hydrochloride and its preparing process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200710019925A CN100579525C (en) | 2007-02-02 | 2007-02-02 | Sustained release preparation of licardipine hydrochloride and its preparing process |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101011395A CN101011395A (en) | 2007-08-08 |
| CN100579525C true CN100579525C (en) | 2010-01-13 |
Family
ID=38699230
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200710019925A Expired - Fee Related CN100579525C (en) | 2007-02-02 | 2007-02-02 | Sustained release preparation of licardipine hydrochloride and its preparing process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100579525C (en) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
| DE10336400A1 (en) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Anti-abuse dosage form |
| DE10361596A1 (en) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Process for producing an anti-abuse dosage form |
| US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
| DE102005005446A1 (en) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Break-resistant dosage forms with sustained release |
| DE102004032049A1 (en) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Anti-abuse, oral dosage form |
| DE102005005449A1 (en) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Process for producing an anti-abuse dosage form |
| DE102007011485A1 (en) | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Dosage form with more difficult abuse |
| TWI454288B (en) | 2008-01-25 | 2014-10-01 | Gruenenthal Chemie | Pharmaceutical dosage form |
| CN101229132B (en) * | 2008-02-03 | 2010-11-24 | 济南宏瑞创博医药科技开发有限公司 | Nimodipine pulse sustained release mircopill preparation and preparing method thereof |
| SI2273983T1 (en) | 2008-05-09 | 2016-11-30 | Gruenenthal Gmbh | Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step |
| JP2012533585A (en) | 2009-07-22 | 2012-12-27 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | Tamper-resistant dosage forms for oxidation-sensitive opioids |
| JP5667183B2 (en) | 2009-07-22 | 2015-02-12 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | Controlled release dosage form with heat melt extrusion |
| US9579285B2 (en) * | 2010-02-03 | 2017-02-28 | Gruenenthal Gmbh | Preparation of a powdery pharmaceutical composition by means of an extruder |
| ES2486791T3 (en) | 2010-09-02 | 2014-08-19 | Grünenthal GmbH | Tamper resistant dosage form comprising an inorganic salt |
| US9636303B2 (en) | 2010-09-02 | 2017-05-02 | Gruenenthal Gmbh | Tamper resistant dosage form comprising an anionic polymer |
| US20130028972A1 (en) | 2011-07-29 | 2013-01-31 | Grunenthal Gmbh | Tamper-resistant tablet providing immediate drug release |
| AR087360A1 (en) | 2011-07-29 | 2014-03-19 | Gruenenthal Gmbh | PROOF OF HANDLING TABLET PROVIDING IMMEDIATE RELEASE OF PHARMACY |
| BR112014019988A8 (en) | 2012-02-28 | 2017-07-11 | Gruenenthal Gmbh | BREAK-RESISTANT DOSAGE FORM COMPRISING A PHARMACOLOGICALLY ACTIVE COMPOUND AND AN ANIONIC POLYMER |
| ES2692944T3 (en) | 2012-04-18 | 2018-12-05 | Grünenthal GmbH | Pharmaceutical dosage form resistant to handling and resistant to rapid discharge of the dose |
| US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
| BR112015026549A2 (en) | 2013-05-29 | 2017-07-25 | Gruenenthal Gmbh | tamper-proof dosage form containing one or more particles |
| WO2014191396A1 (en) | 2013-05-29 | 2014-12-04 | Grünenthal GmbH | Tamper resistant dosage form with bimodal release profile |
| CN105682643B (en) | 2013-07-12 | 2019-12-13 | 格吕伦塔尔有限公司 | Tamper resistant dosage form containing ethylene-vinyl acetate polymer |
| CA2931553C (en) | 2013-11-26 | 2022-01-18 | Grunenthal Gmbh | Preparation of a powdery pharmaceutical composition by means of cryo-milling |
| AU2015261060A1 (en) | 2014-05-12 | 2016-11-03 | Grunenthal Gmbh | Tamper resistant immediate release capsule formulation comprising Tapentadol |
| AU2015266117A1 (en) | 2014-05-26 | 2016-11-24 | Grunenthal Gmbh | Multiparticles safeguarded against ethanolic dose-dumping |
| MX2017013637A (en) | 2015-04-24 | 2018-03-08 | Gruenenthal Gmbh | Tamper-resistant dosage form with immediate release and resistance against solvent extraction. |
| US10842750B2 (en) | 2015-09-10 | 2020-11-24 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
| CN105287435A (en) * | 2015-12-07 | 2016-02-03 | 黑龙江省智诚医药科技有限公司 | Nicardipine hydrochloride sustained release pellets and preparation method thereof |
| CN106902097B (en) * | 2015-12-21 | 2020-01-07 | 瑞普（天津）生物药业有限公司 | A pharmaceutical composition for improving bioavailability of medicine |
| CN112796039B (en) * | 2020-12-30 | 2022-05-20 | 江苏大学 | Preparation method of pH intelligent response controlled-release antibacterial packaging fiber film |
-
2007
- 2007-02-02 CN CN200710019925A patent/CN100579525C/en not_active Expired - Fee Related
Non-Patent Citations (2)
| Title |
|---|
| 盐酸尼卡地平缓释微丸的制备及其稳定性研究. 刘善奎.中国药学杂志，第34卷第11期. 1999 |
| 盐酸尼卡地平缓释微丸的制备及其稳定性研究. 刘善奎.中国药学杂志，第34卷第11期. 1999 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101011395A (en) | 2007-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100579525C (en) | Sustained release preparation of licardipine hydrochloride and its preparing process | |
| TWI778268B (en) | Pharmaceutical combination containing glucokinase promoter and SGLT-2 inhibitor, preparation method and use thereof | |
| JP5285913B2 (en) | Solid release modified pharmaceutical dosage form for oral administration | |
| CN1886119B (en) | Pantoprazole multiparticulate formulations | |
| US11331274B2 (en) | Milrinone controlled-release formulation | |
| KR20040037026A (en) | Oral controlled release pharmaceutical composition for one-a-day therapy for the treatment and prophylaxis of cardiac and circulatory diseases | |
| AU2007307482A1 (en) | Combined preparation for the treatment of cardiovascular diseases based on chronotherapy theory | |
| CN105142618A (en) | Mosapride sustained-release preparation for providing pharmacological clinical effects with once-a-day administration | |
| JPH06239738A (en) | Drug containing s (+) ibuprofen | |
| US20100247645A1 (en) | Pharmaceutical combination of aliskiren and valsartan | |
| CN108289848A (en) | Include the pharmaceutical composition of effective inhibitor of URAT1 | |
| CN103417505A (en) | Huperzine A controlled release preparation having biphasic release behavior, and preparation method thereof | |
| JP2022163681A (en) | Treatment method | |
| CN112451531B (en) | Aspirin and rivaroxaban compound preparation and preparation method thereof | |
| CN106420738B (en) | A kind of sustained release preparation of levamlodipine or its salt and preparation method thereof | |
| CN102600451B (en) | Felodipine ramipril compound sustained-release preparation and preparation method thereof | |
| CN102247326B (en) | Oral chronopharmacologic drug delivery mini-pill preparation of propranolol and its salts | |
| WO2013189305A1 (en) | Valsartan-amlodipine compound solid preparation and preparation method therefor | |
| CN101773482B (en) | Three-stage pulsed release controlled release tablet and preparation method thereof | |
| CN101269056A (en) | Metoprolol salt oral administration impulse pellet preparation | |
| CN106132404A (en) | Metoprolol sustained-release compositions and preparation method thereof | |
| CN102949406A (en) | Compound elvucitabine medicine composition as well as preparation method and use for same | |
| CN115957189A (en) | Ambrisentan preparation and preparation method thereof | |
| JP2012515765A (en) | Pharmaceutical composition for time treatment | |
| CN101269059A (en) | Isosorbide dinitrate oral administration impulse pellet preparations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Nanjing Tefeng Pharmaceutical Co., Ltd. Assignor: Southeast University Contract record no.: 2011320000974 Denomination of invention: Sustained release preparation of licardipine hydrochloride and its preparing process Granted publication date: 20100113 License type: Exclusive License Open date: 20070808 Record date: 20110713 |
|
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100113 Termination date: 20140202 |